Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing the pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. Its pipeline of RAS-targeted oncology drug candidates includes BBO-8520, BBO-10203, and BBO-11818. BBO-8520 (NCT06343402) is a direct inhibitor of KRASG12C in both the ON and OFF states that is being evaluated both as monotherapy and in combination with pembrolizumab in the Phase 1 ONKORAS-101 trial for patients with KRASG12C mutant non-small cell lung cancer. BBO-10203 (NCT06625775) is an orally bioavailable small molecule that selectively and specifically blocks the physical interaction between RAS and PI3Ka, resulting in the inhibition of RAS-driven PI3Ka-AKT signaling in tumors without the risk of hyperglycemia. BBO-11818 (NCT06917079) is a panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states with strong potency against KRASG12D and KRASG12V mutants.

BridgeBio Oncology Therapeutics Ord Shs Profil



Börsenkürzel- -

Name des Unternehmens- -

IPO-datum- -

CEO- -

Anzahl der mitarbeiter- -

Wertpapierart- -

Geschäftsjahresende- -

Addresse- -

Stadt- -

Börse- -

Land- -

Postleitzahl- -

Telefon- -

Website- -

Börsenkürzel- -

IPO-datum- -

CEO- -

Führungskräfte von BridgeBio Oncology Therapeutics Ord Shs



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Idan Elmelech

Chief Operating Officer, Principal Financial Officer

14.15K

-2.42%

Mr. Marc Cobo

Vice President - Finance, Controller, Principal Accounting Officer

13.81K

-2.38%

Mr. Yong Ben, M.D.

Chief Medical and Development Officer

822.00

-127.37%

Ms. Lee Sunyoung, Ph.D.

Vice President - Regulatory Affairs

Mr. Foster Gonsalves, Ph.D.

Vice President - Early Development

Mr. Whan Rhee Joon, Ph.D.

Vice President - Clinical Development

Ms. Kerstin Sinkevicius, Ph.D.

Vice President - Pharmacology

Mr. Jake Bauer

Chairman of the Board

Ms. Chen Bihua

Director

Mr. Peter F. Lebowitz, M.D., Ph.D.